Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
Suspended
University of Vermont
Phase 1/Phase 2
2006-12-01
Atrophic vaginitis is a condition in which the skin lining of the vagina and labia becomes
thin and symptoms develop including vaginal itching, vaginal discomfort and dyspareunia.
These can significantly affect women's comfort, sexuality and quality of life.
Treatment for this condition includes estrogen given in pill form, commonly known as hormone
replacement therapy and local estrogen treatments, such as vaginal estrogen creams and
topical vaginal lubricants. Unfortunately, systemic estrogen is contraindicated in many women
with breast cancer. Some providers also feel that women who are taking aromatase inhibitors
for their breast cancer should also not use local estrogens as several small studies suggest
that these treatments might effect estrogen levels and thus might change how effective the
aromatase inhibitors are. If these women choose not to use any form of estrogen therapy there
symptoms may not be well controlled with other treatments.
The investigators hypothesize that a vaginal testosterone cream might be a safe and effective
alternative treatment for these women. This small study is intended to test the hypothesis
that testosterone cream will not increase estrogen (estradiol) levels and that it will
improve the symptoms of atrophic vaginitis including vaginal dryness, vaginal itching and
pain with intercourse.
The investigators will enroll women in the trial who are taking an aromatase inhibitor and
have the symptoms mentioned above. They will receive a testosterone cream which will be
applied vaginally once a day for 28 days. If good results are found with a prespecified dose
of testosterone, a lower dose will be tested in the next group of women enrolled.
Effects of Fast Acting Testosterone Nasal Spray on Anxiety
Completed
University of Texas at Austin
N/A
2015-02-01
The proposed study will test the effects of a fast-acting testosterone nasal spray on the
fear reactions of young men to two distinct anxiety challenges (social and nonsocial) using a
double-blind randomized experimental design.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
